Researchers evaluated the efficacy of dextromorphan-bupropion among patients with major depressive disorder and comorbid anxiety.
Your search for major depressive disorder returned 224 results
Click on a filter below to refine your search. Remove a filter to broaden your search.
Researchers searched for protective effects in gut microbiota from the pathogenesis of major depressive disorder.
For this study, community-dwelling adults were evaluated for major depressive disorder, generalized anxiety disorder, and global sleep quality over an 18 year period.
Patients with somatoform disorders, major depressive disorder, and healthy controls were recruited between 2016 and 2017 at the Ambulante Psychosoziale Rehabilitation in Austria and Schoen Clinic Roseneck in Germany.
This prospective, multi-center, open-label trial, CAN-BIND-1 was conducted between 2012 and 2017.
Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.
An additional 53.2 million cases of major depressive disorder and 76.2 million cases of anxiety disorders globally were estimated due to the COVID-19 pandemic.
AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
A team of researchers sought to investigate the bidirectional relationship between multiple sclerosis and major depressive disorder with Mendelian randomization.
More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder.
The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.
The researchers analyzed data from a large randomized noninferiority trial that compared theta-burst stimulation and high-frequency (10 Hz) rTMS delivered to the left dorsolateral prefrontal cortex.
This study addresses the question of whether prescription opioid medications has a potentially causal role in the risk for depression and anxiety disorder.
Investigating whether serial ketamine treatments change functional connectivity between limbic structures and resting-state networks.
Patients received 40 Hz gamma tACS to provide data on the use of varying stimulation periods.
Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.
Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.
While the relationship between current mood state and cognitive impairment is unclear, more severe depression has been linked to greater impairment.
The degree of overlap between MDD and burnout is unclear. However, dysfunctional sleep patterns are known risk factors for both conditions.
The influence of gut microbiota extends to the brain via neuroinflammation, resulting in symptoms associated with major depressive disorder.
The Food and Drug Administration (FDA) has granted Fast Track designation to an investigational intranasal formulation of racemic ketamine for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder.
Researchers found evidence for a divergent association between lifetime MDD and the prevalence and severity of symptoms in patients with migraine.
Migraine with active headache may predict other painful physical symptoms in patients with major depressive disorder.
Researchers suggest that improvement in cognitive function should be a goal for major depressive disorder because their data showed little improvement in the cognitive abilities of patients with major depression after treatment with psychological interventions.
Investigators sought to determine the frequency of major depressive disorder in patients in epilepsy clinics.
Migraine was more significantly associated with pain or muscle soreness than anxiety disorders in patients with depression.
Screening recommended for those aged 12 to 18, however there is insufficient evidence to assess for children aged 11 and younger.
Changes to brain structure indicate possible underlying connection to idiopathic major depressive disorder.
American College of Physicians recommends monotherapy with cognitive therapy or second-generation antidepressant for patients in acute phase of moderate-to-severe depression
Deep learning, multidiagnostic model shows high accuracy before clinical examination